« Back
Home /
Talabostat (mesylate)

Talabostat (mesylate)

Item no.	HY-13233A-50mg
Manufacturer	MedChem Express
CASRN	150080-09-4
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.35
Citations	[1]Lankas GR, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005 Oct;54(10):2988-94.\|[2]Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13.\|[3]Talabostat\|[4]Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. Adv Sci (Weinh). 2023 Jun 21;e2300881.\|Adv Sci (Weinh). 2025 Jan 17:e2409147.\|Anal Chem. 2016 Aug 16;88(16):8309-14. \|Biomolecules. 2024 Mar 25, 14(4), 391.\|bioRxiv. 2023 Mar 19.\|bioRxiv. 2023 Nov 4.\|Cancer Commun (Lond). 2024 Mar 20.\|Cancer Res. 2016 Jul 15;76(14):4124-35. \|Cell Rep. 2021 Oct 26;37(4):109904.\|Cell. 2023 May 11;186(10):2144-2159.e22.\|Cell. 2024 Feb 29;187(5):1223-1237.e16.\|J Adv Res. 2024 Oct 5:S2090-1232(24)00433-8.\|J Allergy Clin Immunol. 2021 Jun;147(6):2134-2145.e20.\|J Biol Chem. 2018 Dec 7;293(49):18864-18878. \|J Diabetes Investig. 2021 Sep 8.\|J Exp Med. 2022 Oct 3;219(10):e20212117.\|Nat Commun. 2019 May 7;10(1):2091.\|Neurosci Bull. 2024 Dec 2.\|Obesity. 2020 Dec 20.\|Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120.\|Research Square Preprint. 2024 Apr 18.\|SSRN. 2020 Jul.\|SSRN. 2025 Jan 28.\|Ann Surg Oncol. 2020 Oct;27(11):4337-4347.\|bioRxiv. 2023 Jan 17.\|bioRxiv. 2023 Jun 25.\|bioRxiv. January 25, 2022.\|Cells. 2023 Apr 6, 12(7), 1100.\|CNS Neurosci Ther. 2022 Nov 15.\|Curr Protoc Immunol. 2020 Dec;131(1):e107.\|Int Immunopharmacol. 2023 May 12;120:110291.\|Int J Biol Sci. 2023; 19(2):465-483.\|Iran J Allergy Asthma Immunol. 2021 Mar 17.\|J Biol Chem. 2018 Dec 7;293(49):18864-18878. \|J Immunol. 2020 Sep 15;205(6):1653-1663.\|Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19055-19063. \|Sci Signal. 2023 Jan 17;16(768):eabh1083.\|Science. 2020 Dec 4;370(6521):eaay2002.
Smiles	CC(C)[C@H](N)C(N1[C@H](B(O)O)CCC1)=O.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Val-boroPro (mesylate),PT100 (mesylate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Dipeptidyl Peptidase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	310.18
Product Description	Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 Ki = 0.18 nM) and the inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities[1][2][3].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : ≥ 40 mg/mL\|H2O : 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	Phase 3
Isoform	DPP-4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.